Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A1EWVY8
Tue, 25.04.2023
Formycon AG
Press Release // April 25, 2023
Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
Positive data from extended Phase I pharmacokinetics study complete clinical development program
Phase I and phase III clinical trial program demonstrated comparable safety [ … ]
Tue, 07.02.2023
Formycon AG
Press Release // February 7, 2023
Enno Spillner appointed Chief Financial Officer (CFO) of Formycon AG
Munich, Germany - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced that the Company's Supervisory Board has appointed Mr. Enno Spillner to the Company's Executive Board as Chief Financial Officer (CFO) effective April 1, 2023.
[ … ]
Tue, 07.02.2023
Formycon AG
Press Release // February 7, 2023
Enno Spillner appointed Chief Financial Officer (CFO) of Formycon AG
Munich, Germany - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced that the Company's Supervisory Board has appointed Mr. Enno Spillner to the Company's Executive Board as Chief Financial Officer (CFO) effective April 1, 2023.
[ … ]
Mon, 06.02.2023
Formycon AG
Press Release // February 6, 2023
Aflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 in Phase III Study
MAGELLAN-AMD study demonstrates the comparable efficacy of FYB203 to the reference product Eylea® in patients with neovascular age-related macular degeneration (nAMD)
Primary efficacy endpoint fo [ … ]
Mon, 06.02.2023
Formycon AG
Press Release // February 6, 2023
Aflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 in Phase III Study
MAGELLAN-AMD study demonstrates the comparable efficacy of FYB203 to the reference product Eylea® in patients with neovascular age-related macular degeneration (nAMD)
Primary efficacy endpoint fo [ … ]
Thu, 02.02.2023
Formycon AG
Press Release February 2, 2023
Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), as the exclusive owner of the global commercial rights to FYB202, a biosimilar candidate to Stelara® (ustekinumab), announced [ … ]
Thu, 02.02.2023
Formycon AG
Press Release February 2, 2023
Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), as the exclusive owner of the global commercial rights to FYB202, a biosimilar candidate to Stelara® (ustekinumab), announced [ … ]
Fri, 25.11.2022
Formycon AG
Press Release // November 25, 2022
Formycon Reports its Nine-month Figures for 2022
Group turnover and other operating income totals Euro 28.2 million
Group full-year sales forecast to be about Euro 40 million
EBITDA of Euro -10.9 million and EBIT of Euro -12.1 million correspond to plans due to investments in the Group’s own projects
Nine- [ … ]
Fri, 25.11.2022
Formycon AG
Press Release // November 25, 2022
Formycon Reports its Nine-month Figures for 2022
Group turnover and other operating income totals Euro 28.2 million
Group full-year sales forecast to be about Euro 40 million
EBITDA of Euro -10.9 million and EBIT of Euro -12.1 million correspond to plans due to investments in the Group’s own projects
Nine- [ … ]
Thu, 03.11.2022
Formycon AG
Press Release // November 3, 2022
Broad-acting antiviral SARS-CoV-2 drug FYB207 shows longer half-life and improved efficacy through optimized molecular design in preclinical studies
Protein and glycoengineering improve pharmacokinetics and efficacy
Half-life of more than 14 days comparable to the bioavailability of an antibody
Reduction of vi [ … ]